Right patient, right drug, right trial. Under two years from company creation to a first trial is wild, and for ME/CFS patients who've been told it's all in their head for decades, this is HUGE. Rooting for you @fidjissimo 💪
And just like that, we have our first clinical trial and pharma partnership in the works! We’re teaming up with Prolong to take the drug they developed for stroke and see if it can help our patients with ME/CFS by increasing oxygen delivery and blood flow. Thanks to the 200TB of data @chroniclebioAI has amassed, combined with our AI engine, we are identifying patients that show hypoxia so we can focus this trial on them.View quoted post on X
This is really the promise of the company: understanding biology at such a deep level that we can match the exact right patients to the exact right drugs and massively increase the likelihood of success of trials.
Going from company creation to first trial in less than two years is pretty cool, but there’s still a lot of work to be done to prove we can improve patients’ lives. One step at a time.